Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
23,020.00
(
-2.10%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
101.72
(
2.98%
)
Bitcoin
69,015.80
(
-3.21%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 205372

Thursday, 12/08/2016 10:13:09 AM

Thursday, December 08, 2016 10:13:09 AM

Post# of 257295
GILD submits NDA for SOF/VEL/VOX HCV regimen as salvage therapy for patients who failed DAA regimens including an NS5A inhibitor:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2228502

The specified duration of treatment is 12 weeks for all genotypes (with or without cirrhosis), so my commentary at the bottom of #msg-125928919 appears to have been accurate.

SOF/VEL/VOX consists of 400mg Sovaldi (nuke), 100mg Velpatasvir (NS5A), and 100mg Voxilaprevir (PI; f/k/a GS-9857), co-formulated as a single daily pill.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today